simtuzumab

Showing 1 posts of 1 posts found.

Gilead logo

Gilead terminates Phase II simtuzumab IPF study

January 6, 2016
Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab

Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …

Latest content